Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Exsilio launches for messenger RNA genomic medicine

by Sarah Braner
July 11, 2024 | A version of this story appeared in Volume 102, Issue 21

 

Exsilio Therapeutics has launched with $82 million in series A funding. Exsilio uses lipid nanoparticles and messenger RNA (mRNA) to integrate whole corrective genes into “safe harbors” in the genome.The firm will deploy the funds to further develop the platform and establish a presence in Boston. It is also seeking a replacement for interim CEO Tal Zaks, the former chief medical officer of Moderna.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.